| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.06 | 0.2 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.032 | 0.2 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.04 | 0.2 |